Skip to content
Life Sciences Series A Founded 2021

CRISPR QC

Provider of real-time CRISPR gene editing analysis. It offers solutions for measuring RNP formation, DNA target binding, and cleavage activity. The platform enables researchers to optimize gRNA design, improve CRISPR efficiency, and accelerate breakthroughs in gene editing workflows. This allows for early detection of issues, reducing troubleshooting time and maximizing resource utilization. The company was founded…

📍 San Diego, United States · Genomics

Funding snapshot

Last roundSeries A
Amount$10M
Date2 January 2024
Total raised$12M
Team size11

About

Provider of real-time CRISPR gene editing analysis. It offers solutions for measuring RNP formation, DNA target binding, and cleavage activity. The platform enables researchers to optimize gRNA design, improve CRISPR efficiency, and accelerate breakthroughs in gene editing workflows. This allows for early detection of issues, reducing troubleshooting time and maximizing resource utilization. The company was founded in 2021 and headquartered in San Diego, United States. It has raised $12.5M in series a funding, with backing from Serra Ventures, Xcellerant Ventures, EvoNexus, BioBrit, and others. The company operates in the Life Sciences - Genomics space. The company leverages advanced technology to deliver innovative solutions tailored to its target market, addressing key industry challenges and driving value for its customers.

Business model

Genomics > Enabling Technologies > Technology Platforms > Gene Editing

Institutional investors

Serra Ventures Xcellerant Ventures EvoNexus BioBrit SUNCOAST VENTURES

Latest coverage

No articles yet.

Raising like CRISPR QC?

Analyze your pitch deck before your next raise.

Analyze My Deck →